EMAP-II in metabolic syndrome
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: тo determine the serum level of EMAP-II as a marker of endothelial dysfunction in patients with metabolic syndrome, to study its relationship with the other risk factors for cardiovascular disease.
Materials and methods. We examined 23 patients with WHO criteria of metabolic syndrome, 30 patient with ATP III criteria of metabolic syndrome, 18 – IDF criteria, 22 healthy control subjects. The content of EMAP-II was determined by an enzyme immunoassay using the Amprer column (Amersham Lifesilence) and the Amersham pharmacia biotech test system (England). Serum levels of EMAP-II were determined by immunoenzyme assay. The data were presented as means±SD. Statistical analysis was performed using the Student test, Person rank correlation coefficient.
Results. We found an increased serum level of EMAP-II in patients with WHO, ATP III, IDF criteria of metabolic syndrome compared to control group (4,22±1,96 ng/ml, 3,95±2,04 ng/ml, 3,92±2,04 ng/ml and 1,46±0,65 ng/ml respectively; р<0,05). Also, the level of EMAP-II correlated with key markers of insulin resistance, carbohydrate and lipid metabolism (p<0,05).
Conclusion. The revealed changes of EMAP-II serum levels could reflect an endothelial dysfunction in patients with metabolic syndrome. Insulin resistance, hyperglycaemia, dyslipidemia appear to be significant contributing factor to the elevation of EMAP-II.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Adegbija O., Hoy W.E., Wang Z. Waist circumference values equivalent to body mass index points for predicting absolutecardiovascular disease risks among adults in an Aboriginal community: a prospective cohort study// BMJ Open. – 2015. – V. 5 (11). – P. 009185. http://dx.doi.org/10.1136/bmjopen-2015-009185
Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome: a new worldwide definition// Lancet. – 2005. – V. 366. – P. 1059–1062. https://doi.org/10.1016/S0140-6736(05)67402-8
DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 // Diabetologia. – 2010. – V. 53. – P. 1270–1287. https://doi.org/10.1007/s00125-010-1684-1
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) // JAMA. – 2001. – V. 285. – P. 2486–2497. https://doi.org/10.1001/jama.285.19.2486
ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension // J Hypertens. – 2013. – V. 10. – Р. 1925–38. https://doi.org/10.1097/HJH.0b013e328364ca4c
Husain K., Hernandez W., Ansari R.A., Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis // World J Biol Chem. – 2015. – V. 6 (3). – P. 209–17. https://doi.org/10.4331/wjbc.v6.i3.209
Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man // Diabetologia. – 1985. – V. 28. – P. 412–419. https://doi.org/10.1007/BF00280883
Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease // Circulation. – 2002. – V. 106 (3). – P. 286–8. https://doi.org/10.1161/01.CIR.0000019884.36724.D9
World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization, 1999. http://apps.who.int/iris/handle/10665/66040
Van Horssen R., Eggermont A.M., ten Hagen T.L. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes // Cytokine Growth Factor Rev. – 2006. – V. 17 (5). – P. 339–48. https://doi.org/10.1016/j.cytogfr.2006.08.001
Zhang J., Wang D., He S. Roles of antibody against oxygenized low density lipoprotein in atherosclerosis: recent advances // Int J Clin Exp Med. – 2015. – V. 8 (8). – P. 11922–9.
